Business
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to school, volunteer or actively look for employment. About one in five surveyed working adults with TD reported quitting their job due to TD symptoms prior to treatment.1 Findings are released in recognition of Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of increased awarenes
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Respondents also reported missing an average of 8 hours of work or school per week due to tardive dyskinesia prior to treatment1","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings released during Tardive Dyskinesia Awareness Week","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":322,"olType":false},{"type":"text","content":"SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to school, volunteer or actively look for employment. About one in five surveyed working adults with TD reported quitting their job due to TD symptoms prior to treatment.1 Findings are released in recognition of Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of increased awareness, early recognition and appropriate management of TD.","length":597,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmdenVtXM7LFmbrt7BNiag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMA--/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74}},"href":"https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""These findings highlight how uncontrolled, involuntary movements associated with tardive dyskinesia can lead to reduced job responsibilities or even loss of employment," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "This reinforces the importance of routine screening for tardive dyskinesia in clinical practice, including evaluation of its impact on patients' and caregivers' lives so that a...